Literature DB >> 28646517

Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens.

Preetesh Jain1, Hagop Kantarjian1, Nitin Jain1, Nicholas J Short1, Cameron C Yin2, Rashmi Kanagal-Shamanna2, Joseph Khoury2, Marina Konopleva1, Koji Sasaki1, Tapan M Kadia1, Rebecca Garris1, Sherry Pierce1, Zeev Estrov1, William Wierda1, Jorge Cortes1, Susan O'Brien3, Farhad Ravandi1, Elias Jabbour1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28646517      PMCID： PMC5689471          DOI： 10.1002/ajh.24833

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  8 in total

1.  The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.

Authors:  P Jain; H Kantarjian; F Ravandi; D Thomas; S O'Brien; T Kadia; J Burger; G Borthakur; N Daver; E Jabbour; M Konopleva; J Cortes; N Pemmaraju; M A Kelly; M Cardenas-Turanzas; R Garris; S Faderl
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

2.  T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses.

Authors:  Katia Basso; Lara Mussolin; Antonella Lettieri; Manisha Brahmachary; Wei Keat Lim; Andrea Califano; Giuseppe Basso; Andrea Biondi; Giovanni Cazzaniga; Angelo Rosolen
Journal:  Genes Chromosomes Cancer       Date:  2011-08-30       Impact factor: 5.006

3.  Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.

Authors:  Dieter Hoelzer; Nicola Gökbuget; Werner Digel; Thomas Faak; Michael Kneba; Regina Reutzel; Joanna Romejko-Jarosinska; Jacek Zwolinski; Jan Walewski
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

Authors:  Jacob M Rowe; Georgina Buck; Alan K Burnett; Raj Chopra; Peter H Wiernik; Susan M Richards; Hillard M Lazarus; Ian M Franklin; Mark R Litzow; Niculae Ciobanu; H Grant Prentice; Jill Durrant; Martin S Tallman; Anthony H Goldstone
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

Review 5.  T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?

Authors:  Dieter Hoelzer; Nicola Gökbuget
Journal:  Clin Lymphoma Myeloma       Date:  2009

6.  Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.

Authors:  Deborah A Thomas; Susan O'Brien; Jorge Cortes; Francis J Giles; Stefan Faderl; Srdan Verstovsek; Alessandra Ferrajoli; Charles Koller; Miloslav Beran; Sherry Pierce; Chul S Ha; Fernando Cabanillas; Michael J Keating; Hagop Kantarjian
Journal:  Blood       Date:  2004-06-03       Impact factor: 22.113

7.  T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

Authors:  David I Marks; Elisabeth M Paietta; Anthony V Moorman; Susan M Richards; Georgina Buck; Gordon DeWald; Adolfo Ferrando; Adele K Fielding; Anthony H Goldstone; Rhett P Ketterling; Mark R Litzow; Selina M Luger; Andrew K McMillan; Marc R Mansour; Jacob M Rowe; Martin S Tallman; Hillard M Lazarus
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

8.  High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).

Authors:  E Jabbour; S Koscielny; C Sebban; N Peslin; C Patte; T Gargi; P Biron; C Fermé; J H Bourhis; J M Vantelon; P Arnaud; V Ribrag
Journal:  Leukemia       Date:  2006-05       Impact factor: 11.528
  8 in total
  1 in total

1.  Clinical Outcomes of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System.

Authors:  Effrosyni Apostolidou; Curtis Lachowiez; Harinder S Juneja; Wei Qiao; Onyebuchi Ononogbu; Courtney Nicole Miller-Chism; Mark Udden; Hilary Ma; Martha Pritchett Mims
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2021-07-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.